Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: BI 1356Drug: placebo
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 133
- Registration Number
- NCT00800683
- Locations
- 🇺🇸
1218.43.10013 Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States
🇺🇸1218.43.10009 Boehringer Ingelheim Investigational Site, West Palm Beach, Florida, United States
🇺🇸1218.43.10018 Boehringer Ingelheim Investigational Site, Decatur, Georgia, United States
Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 857
- Registration Number
- NCT00798161
- Locations
- 🇨🇦
1218.46.11003 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
🇨🇦1218.46.11002 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada
🇨🇦1218.46.11006 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 937
- Registration Number
- NCT00796653
- Locations
- 🇨🇦
1222.14.4007 Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada
🇩🇪1222.14.4103 Boehringer Ingelheim Investigational Site, Frankfurt, Germany
🇮🇹1222.14.4301 Boehringer Ingelheim Investigational Site, Cassano Delle Murge (ba), Italy
Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder
- Conditions
- Bladder, Neurogenic
- Interventions
- Drug: PlaceboDrug: tamsulosin hydrochloride
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 231
- Registration Number
- NCT00796614
BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: BiBW 2992
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT00796549
- Locations
- 🇮🇹
1200.40.39008 Boehringer Ingelheim Investigational Site, Modena, Italy
🇮🇹1200.40.39005 Boehringer Ingelheim Investigational Site, Monza (MI), Italy
🇮🇹1200.40.39011 Boehringer Ingelheim Investigational Site, Arezzo, Italy
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 906
- Registration Number
- NCT00793624
- Locations
- 🇫🇮
1222.13.2101 Boehringer Ingelheim Investigational Site, Tampere, Finland
🇲🇾1222.13.3102 Boehringer Ingelheim Investigational Site, Kuala Lumpur, Malaysia
🇫🇮1222.13.2102 Boehringer Ingelheim Investigational Site, Turku, Finland
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: BI201335Drug: Placebo
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT00793793
- Locations
- 🇺🇸
1220.2.10 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
🇺🇸1220.2.15 Boehringer Ingelheim Investigational Site, San Francisco, California, United States
🇺🇸1220.2.17 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 408
- Registration Number
- NCT00789035
- Locations
- 🇩🇪
1245.9.49004 Boehringer Ingelheim Investigational Site, Hamburg, Germany
🇮🇹1245.9.39004 Boehringer Ingelheim Investigational Site, Siena, Italy
🇦🇷1245.9.54001 Boehringer Ingelheim Investigational Site, Capital Federal, Argentina
12 / 48 Week Pivotal PFT vs PBO in COPD I
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Olodaterol (BI1744)Drug: placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 625
- Registration Number
- NCT00782210
- Locations
- 🇺🇸
1222.11.1116 Boehringer Ingelheim Investigational Site, Berkeley, California, United States
🇨🇳1222.11.1168 Boehringer Ingelheim Investigational Site, Xi'An, China
🇺🇸1222.11.1110 Boehringer Ingelheim Investigational Site, Deland, Florida, United States
12 / 48 wk Pivotal PFT vs PBO in COPD II
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Olodaterol (BI 1744)Drug: Placebo
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 644
- Registration Number
- NCT00782509
- Locations
- 🇺🇸
1222.12.1227 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States
🇺🇸1222.12.1208 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States
🇨🇳1222.12.1287 Boehringer Ingelheim Investigational Site, Taipei, Taiwan